The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $17.34

Today's change+0.09 +0.52%
Updated July 31 4:01 PM EDT. Delayed by at least 15 minutes.
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $17.34

Today's change+0.09 +0.52%
Updated July 31 4:01 PM EDT. Delayed by at least 15 minutes.

Boston Scientific Corp up (U.S.)$0.09

Boston Scientific Corp closed up Friday by (U.S.)$0.09 or 0.52% to (U.S.)$17.34. Over the last five days, shares are unchanged, but have gained 30.87% over the last year to date. This security has outperformed the S&P 500 by 26.71% during the last year.

Key company metrics

  • Open(U.S.) $17.34
  • Previous close(U.S.) $17.25
  • High(U.S.) $17.47
  • Low(U.S.) $17.24
  • Bid / Ask(U.S.) $17.11 / (U.S.) $17.44
  • YTD % change+30.87%
  • Volume6,842,415
  • Average volume (10-day)8,941,028
  • Average volume (1-month)8,163,689
  • Average volume (3-month)9,167,133
  • 52-week range(U.S.) $11.10 to (U.S.) $18.62
  • Beta1.16
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward19.05×
  • Forward PEG1.73×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.12
Updated July 31 4:01 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.60%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue1,8431,7681,8871,846
Total other revenue--------
Total revenue1,8431,7681,8871,846
Gross profit1,3031,2561,3371,305
Total cost of revenue540512550541
Total operating expense1,6241,7442,3791,782
Selling / general / administrative700660746735
Research & development220192208212
Depreciation / amortization116113111109
Interest expense (income), net operating--------
Unusual expense (income)30250739164
Other operating expenses, total18172521
Operating income21924-49264
Interest income (expense), net non-operating-106-60-55-54
Gain (loss) on sale of assets--------
Other--------
Income before tax105-51-5543
Income after tax102-1-29943
Income tax, total3-50-255-40
Net income102-1-29943
Total adjustments to net income--------
Net income before extra. items102-1-29943
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items102-1-29943
Inc. avail. to common incl. extra. items102-1-29943
Diluted net income102-1-29943
Dilution adjustment--00--
Diluted weighted average shares1,3621,3341,3271,348
Diluted EPS excluding extraordinary itemsvalue per share0.070.00-0.230.03
Dividends per sharevalue per share--0.00--0.00
Diluted normalized EPSvalue per share0.100.120.140.11